Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abiomed Inc.

www.abiomed.com

Latest From Abiomed Inc.

Global Device Approvals, Weekly Snapshot: Teleflex, Abiomed Gain Cardio Approvals

A snapshot of global device approvals captured during the past week in Medtech Insight's Approvals Tracker. This week, Teleflex's recently acquired Essential Medical business gained US approval for a closely watched vascular closure device and Abiomed gained a CE mark for a remote monitoring technology.

Into 2019: Meaningful Innovation In Medtech Is Reaching A 10-Year Peak

Medtech continues to outperform biotech from a sustainable investment growth point of view, and meanwhile medtech CEOs are on message about advancing value- and outcomes-based models with their provider partners. It all points to medtech being in a good place for 2019, and there is no reason for M&A and industry consolidation to stop anytime soon, says Jefferies equity analyst Raj Denhoy.

Financing M & A

MTI 100: Major M&A Bookends Year Of Mainly Steady Growth For Leading Medtech Groups

In Medtech Insight's latest rankings of top 100 revenue-earners in the medical device and diagnostics sector, it was steady as she goes for most of the multinational medtechs, with some major exceptions. But there will be more M&A reflected in next year's ranking based on 2018 revenues. Also, medtech groups leading the global market tightened their grip further in 2017, as providers chose to partner more and more with fewer suppliers who can offer a wider provision of services.

Commercial M & A

Abiomed Touts New Study Results, Potential To Revolutionize Heart-Attack Treatment

Promising new results from a pilot study of Abiomed’s Impella device to reduce damage after myocardial infarction sets the company up to start a pivotal study, which, if successful, could change how patients are treated immediately after an attack.

Clinical Trials Research & Development
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
    • Monitoring Equipment & Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Abiomed Inc.
  • Senior Management
  • Michael R Minogue, Pres. & CEO
    Todd A Trapp, CFO
    Michael Howley, VP, General Mgr., Global Sales
    Seth Bilazarian, MD, CMO
    David Weber, COO
  • Contact Info
  • Abiomed Inc.
    Phone: (508) 777-5410
    22 Cherry Hill Dr.
    Danvers, MA 01923
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register